蒙古乌兰巴托儿童接种13价肺炎球菌结合疫苗前后鼻咽部肺炎球菌携带情况
该研究在蒙古乌兰巴托两个区开展两次横断面调查,比较PCV13引入前(2015年)与引入后一年(2017年)5-8周龄和12-23月龄儿童的鼻咽部肺炎球菌携带。结果显示12-23月龄儿童PCV13血清型携带率下降52%,5-8周龄下降51%,同时非PCV13血清型在12-23月龄出现替代(aPR 1.55),且疫苗后肺炎球菌密度增加,抗菌素耐药基因普遍存在。
要点
- PCV13引入一年后,12-23月龄儿童PCV13血清型携带率下降52%(aPR 0.48)。
- 5-8周龄儿童PCV13血清型携带率下降51%(aPR 0.49),非PCV13无显著变化。
- 12-23月龄儿童非PCV13血清型携带率上升(aPR 1.55),提示血清型替换。
核心结论
- PCV13引入一年后对蒙古儿童肺炎球菌携带产生实质性影响,PCV13血清型携带率显著下降,但非PCV13血清型在12-23月龄儿童中出现替代,需进一步监测。
研究设计与样本
- 在乌兰巴托两个区的社区健康诊所开展两次横断面携带调查,分别于2015年5-7月和2017年5-7月进行。
- 分析纳入961名5-8周龄(年龄太小未接种疫苗)儿童和989名12-23月龄(符合接种条件)儿童。
- 采用定量实时PCR检测肺炎球菌,并用DNA微阵列进行分子血清分型。
主要发现
- 12-23月龄儿童PCV13血清型携带率下降52%(aPR 0.48,95%CI 0.39-0.59),非PCV13血清型携带率上升(aPR 1.55,95%CI 1.30-1.85)。
- 5-8周龄儿童PCV13血清型携带率下降51%(aPR 0.49,95%CI 0.33-0.73),非PCV13血清型携带率无显著变化(aPR 1.10,95%CI 0.83-1.46)。
- PCV13引入后,PCV13和非PCV13肺炎球菌密度均增加。
- 82.3%的样本含有至少一种所检测的10种抗菌素耐药基因。
临床怎么用
- PCV13接种可显著降低疫苗血清型肺炎球菌携带,预期可减少相应肺炎球菌疾病并产生间接保护效应。
- 需持续监测非PCV13血清型替换及肺炎球菌密度变化,以评估疫苗长期效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nasopharyngeal carriage of Streptococcus pneumoniae precedes disease, is the source of pneumococcal community spread, and the mechanism for herd protection provided by pneumococcal conjugate vaccines (PCVs). There are few PCV impact studies in low- and middle-income countries, particularly in Asia. In 2016, Mongolia introduced the 13-valent PCV (PCV13) in a phased manner using a 2 + 1 schedule, with catch-up. We aimed to assess the impact of PCV13 introduction on nasopharyngeal pneumococcal carriage and density in children in Mongolia. METHODS: We conducted two cross-sectional carriage surveys (pre- and one year post-PCV) at community health clinics in two districts of the capital city, Ulaanbaatar in both May-July 2015 and 2017. The study analysis included 961 children too young to be vaccinated (5-8 weeks old) and 989 children eligible for vaccination (12-23 months old). Pneumococci were detected by quantitative real-time PCR and molecular serotyping performed using DNA microarray. FINDINGS: One year post-PCV introduction, PCV13 serotype carriage reduced by 52% in 12-23 month olds (adjusted prevalence ratio [aPR] 0.48 [95% confidence interval [CI] 0.39-0.59]), with evidence of non-PCV13 serotype replacement (aPR 1.55 [95% CI 1.30-1.85]), compared with the pre-PCV period. In 5-8 week olds, PCV13 serotype carriage reduced by 51% (aPR 0.49 [95% CI 0.33-0.73]) with no significant change in non-PCV13 serotype carriage (aPR 1.10 [95% CI 0.83-1.46]). An increase was observed in both PCV13 and non-PCV13 pneumococcal density post-PCV introduction. Antimicrobial resistance (AMR) genes were common, with 82.3% of samples containing at least one of the 10 AMR genes assessed. CONCLUSION: This study demonstrates substantive PCV13 impact on pneumococcal carriage one year post-vaccine introduction in Mongolia. The reductions in PCV13 serotype carriage are likely to result in reductions in pneumococcal disease including indirect effects. Increases in non-PCV13 serotypes require further monitoring.
引用
- von Mollendorf C, Dunne EM, La Vincente S, et al. Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine. Vaccine. 2019. PMID: 31174939. doi:10.1016/j.vaccine.2019.05.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。